Compile Data Set for Download or QSAR
Report error Found 520 Enz. Inhib. hit(s) with all data for entry = 10013
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311622(Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...)
Affinity DataIC50: 0.100nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311639(Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...)
Affinity DataIC50: 0.100nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311679(Ex. Cpd. 131 | US10807986, Example 131 | US1104669...)
Affinity DataIC50: 0.100nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311705(Ex. Cpd. 157 | US10807986, Example 157 | US1104669...)
Affinity DataIC50: 0.100nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311600(Ex. Cpd. 37 | US10807986, Example 37 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311634(Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311635(Ex. Cpd. 87 | US10807986, Example 87 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311636(Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311643(Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311651(Ex. Cpd. 103 | US10807986, Example 103 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311652(Ex. Cpd. 104 | US10807986, Example 104 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311653(Ex. Cpd. 105 | US10807986, Example 105 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM508562(US11046696, Compound 112)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311673(Ex. Cpd. 125 | US10807986, Example 125 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311691(Ex. Cpd. 143 | US10807986, Example 143 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311703(Ex. Cpd. 155 | US10807986, Example 155 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311704(Ex. Cpd. 156 | US10807986, Example 156 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311707(Ex. Cpd. 159 | US10807986, Example 159 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311708(Ex. Cpd. 160 | US10807986, Example 160 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311717(Ex. Cpd. 169 | US10807986, Example 169 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311734(Ex. Cpd. 186 | US10807986, Example 186 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311736(Ex. Cpd. 188 | US10807986, Example 188 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311751(Ex. Cpd. 205 | US10807986, Example 205 | US1104669...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311586(Ex. Cpd. 23 | US10807986, Example 23 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311618(Ex. Cpd. 55 | US10807986, Example 55 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311638(Ex. Cpd. 90 | US10807986, Example 90 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311641(Ex. Cpd. 93 | US10807986, Example 93 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311642(Ex. Cpd. 94 | US10807986, Example 94 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311658(Ex. Cpd. 110 | US10807986, Example 110 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311711(Ex. Cpd. 163 | US10807986, Example 163 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311720(Ex. Cpd. 172 | US10807986, Example 172 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311730(Ex. Cpd. 182 | US10807986, Example 182 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311731(Ex. Cpd. 183 | US10807986, Example 183 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311733(Ex. Cpd. 185 | US10807986, Example 185 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311739(Ex. Cpd. 191 | US10807986, Example 191 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311741(Ex. Cpd. 193 | US10807986, Example 193 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311743(Ex. Cpd. 195 | US10807986, Example 195 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311746(Ex. Cpd. 198 | US10807986, Example 198 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311752(Ex. Cpd. 206 | US10807986, Example 206 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311622(Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311634(Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311639(Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311643(Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311651(Ex. Cpd. 103 | US10807986, Example 103 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311699(Ex. Cpd. 151 | US10807986, Example 151 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311700(Ex. Cpd. 152 | US10807986, Example 152 | US1104669...)
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 520 total ) | Next | Last >>
Jump to: